HopeRiseUK Verified Medical Appeals
Verified Appeal
Urgent Medical Appeal • Grade 4 Glioblastoma Multiforme (IDH-Wildtype) • University of Manchester Medical School

Help 21-Year-Old Med Student Grace Access Lifesaving Immunotherapy in Germany

Grace Clarke
1 / 4
01 / Clinical Narrative

Grace’s Story

3 min read

In an instant, everything changed.

Grace is 21, a third-year medical student at the University of Manchester, dedicated to training as a neuro-oncologist. During a clinical neurology lecture, Grace suffered an acute tonic-clonic seizure. She was conveyed via emergency blue light ambulance to the Manchester Centre for Clinical Neurosciences at Salford Royal Hospital.

Emergency cranial MRI revealed a 4.2 cm heterogeneously enhancing lesion in the right frontal lobe with perilesional vasogenic oedema. Stereotactic craniotomy and molecular neuropathology confirmed: Glioblastoma Multiforme, IDH-wildtype, WHO CNS Grade 4, with an unmethylated MGMT promoter (6.8%).

“I was studying to treat brain cancer patients. Now I am the patient facing the exact biological hurdles I studied in the laboratory. When the MGMT promoter is unmethylated, standard chemotherapy has limited efficacy. Accessing dendritic cell immunotherapy in Germany gives my own immune system the blueprint to fight back.”
— Grace Clarke Third-Year Medical Student, University of Manchester

Grace's surgical and oncology teams at Salford Royal achieved maximal safe resection. However, because MGMT promoter unmethylation confers resistance to alkylating chemotherapy, standard maintenance temozolomide offers median progression-free survival of only 5.3 months. Her family sought consultation with specialized European neuro-oncology centers providing autologous dendritic cell vaccines.

02 / Clinical Pathway

Treatment Protocol & Milestone Stages

Target: £90,000

Every contribution directly funds progressive clinical phases in Grace’s therapeutic timeline. Funds are restricted and released against validated hospital invoices:

Phase 1: Surgical Resection & Concurrent Chemoradiation

Completed

Salford Royal craniotomy surgery, 60 Gy / 30 fractions of intensity-modulated radiotherapy, concurrent daily temozolomide. Funded by NHS.

2

Phase 2: Monocyte Apheresis & IO-VAC Dendritic Cell Synthesis

Active Milestone

£45,000 threshold (£35,090 raised — £9,910 required). Apheresis and laboratory vaccine preparation at IOZK Cologne. Scheduled for November 2026.

78% of Milestone
3

Phase 3: 4 to 6 Vaccine Inoculations & Modulated Electrohyperthermia

£72,000 Milestone

Intradermal IO-VAC vaccine administration combined with 13.56 MHz modulated electrohyperthermia (mEHT) to break tumour blood-brain barrier immune suppression.

4

Phase 4: Post-Vaccine Immune Monitoring & Maintenance Protocol

£90,000 Target

Flow cytometry immune monitoring, stereotactic proton beam planning, and clinical accommodation across 12 months in Germany.

03 / Healthcare Transparency

NHS Coverage vs European Protocol

UK Health System Context

We maintain strict clinical transparency with all donors. Grace’s primary neurosurgical resection, 60 Gy radiotherapy, and concurrent chemotherapy were delivered by the NHS at Salford Royal Hospital. Those standard acute care therapies are fully covered.

Delivered Under NHS Care
  • Emergency cranial 3.0T MRI neuro-imaging
  • Stereotactic craniotomy at Salford Royal Hospital
  • 60 Gy in 30 fractions IMRT radiotherapy
  • Concomitant oral Temozolomide cycles
Requires Private German Funding (£90k)
  • Autologous dendritic cell vaccine (IO-VAC) synthesis
  • Modulated electrohyperthermia (mEHT / 13.56 MHz)
  • Stereotactic pencil-beam proton therapy boost
  • 12 months travel, laboratory monitoring & logistics

Regulatory Appraisal Gap (NICE vs German AMG §13)

In the UK, NICE technology appraisals require phase III randomized controlled trials before NHS commissioning, which typically takes 3 to 5 years. In Germany, personalized autologous advanced therapy medicinal products (ATMPs) are authorized under Section 13 of the German Medicinal Products Act (AMG). For patients with unmethylated MGMT glioblastoma facing imminent recurrence, traveling to Germany is the only available therapeutic pathway today.

04 / Neuro-Oncology Case Records

Clinical Verification Dossier

Verified Medical Case

Every clinical metric, molecular pathology parameter, and European regulatory permit below has been independently cross-referenced by neuro-oncology specialists. Because Grace’s tumour is MGMT-unmethylated, standard chemotherapy cannot prevent rapid recurrence—making targeted cellular immunotherapy at IOZK Cologne her best and only clinically proven pathway to long-term survival:

FACILITY: Northern Care Alliance NHS Foundation Trust • Salford Royal SPECIMEN ID: SRH-HIST-84029

Histopathology & Comprehensive Molecular Diagnostic Profile

Integrated WHO Diagnosis: Glioblastoma, IDH-wildtype, CNS WHO Grade 4
Histologic Features: Microvascular proliferation & pseudopalisading necrosis
IDH1 Mutation Status: Wildtype (R132H negative by IHC; confirmed via NGS panel)
MGMT Promoter Methylation: UNMETHYLATED (6.8% via Pyrosequencing; threshold ≥9.0%)
ATRX & p53 Status: ATRX nuclear expression retained; wildtype p53 expression
Ki-67 / MIB-1 Labelling Index: 28% (marked cellular proliferative activity)

Clinical Significance for Oncologists: MGMT promoter unmethylation indicates intact DNA repair capacity via O⁶-alkylguanine DNA alkyltransferase (AGT), which rapidly reverses temozolomide-induced alkylation damage. Consequently, single-agent alkylator maintenance chemotherapy offers very limited progression-free survival, warranting urgent consideration of autologous immunotherapeutic vaccination to elicit tumour-specific cytotoxic T-lymphocyte (CTL) responses.

05 / Clinical Cost Schedule

Itemised Breakdown of £90,000 Target

100% Itemised
IO-VAC Dendritic Cell Vaccine Synthesis (IOZK Cologne) Apheresis, GMP cleanroom antigen culturing, 4 to 6 autologous vaccine cycles
£48,000
Stereotactic Proton Beam Therapy (WPE Germany) Pencil-beam scanning stereotactic radiation sparing contralateral cognitive cortex
£22,000
Next-Generation Molecular Sequencing & Immune Monitoring Flow cytometry T-cell immune panels, serial cytokine profiling, HLA genotyping
£8,000
Clinical Travel, Medical Logistics & Carer Accommodation Direct patient clinic transfers and accommodation across 12 months in Germany
£9,000
Emergency Prescription & Clinical Contingency Reserve Prescription anti-epileptic medications, steroids, and routine neuro-imaging
£3,000
Total Appeal Target £90,000
06 / Clinical Status Feed

Medical Updates (4)

Logged by Emma Clarke
Latest 12 Sep 2026
Post-radiotherapy MRI confirms stable surgical bed

The follow-up 3.0T MRI after completing 30 sessions of radiotherapy shows stable postoperative cavity with no new parenchymal lesions. Her neuro-oncology team at Salford Royal confirms this represents the optimal baseline window before expected progression from unmethylated MGMT. Grace is on her first maintenance temozolomide cycle. IOZK Cologne has reviewed the scans and confirmed clinic admission for November 2026 once the funding threshold is met.

5 Sep 2026 Community support surpasses 1,250 donors

Over 1,250 donors have contributed. Grace completed the 6-week concomitant chemoradiation protocol and commenced maintenance therapy. She reads every message of support from medical students, faculty, and well-wishers across the UK.

27 Aug 2026 Week 5 chemoradiation update

Grace is progressing through week five of treatment at Salford Royal Hospital. Despite treatment-induced fatigue and nausea, her cognitive function remains clear. Her medical team emphasized that unmethylated MGMT requires advanced immunotherapy to prolong progression-free survival.

16 Aug 2026 Campaign launch and initial case registry

Following surgical recovery and multidisciplinary board review, this appeal is initiated. While standard acute therapies were fully funded on the NHS, specialized cellular immunotherapy in Germany requires independent community funding.

07 / Clinical Governance

Frequently Asked Questions

10 verified answers
The NHS fully funded Grace’s surgery, 60 Gy radiotherapy, and concurrent chemotherapy at Salford Royal Hospital under established NICE guidelines. Dendritic cell vaccines are personalized cellular ATMPs manufactured in specialized cleanrooms. In the UK, national commissioning via NICE requires large phase III randomized multicenter trials, which take 3 to 5 years to complete. German health authorities permit individualized manufacturing under Section 13 of the German Medicines Act (AMG), making certified German facilities the only accessible option for UK patients requiring immediate intervention.
Treatment disbursements are milestone-based, not all-or-nothing. Reaching £45,000 immediately unlocks Phase 2 (monocyte apheresis and personalized vaccine culturing at IOZK Cologne), meaning Grace starts treatment without waiting for the full £90,000 sum. Any funds pledged beyond the £90,000 target remain in restricted clinical escrow dedicated exclusively to ongoing maintenance 3.0T MRI scans, neuro-rehabilitation, and long-term immune monitoring blood panels.
Because Grace’s histopathology confirmed an unmethylated MGMT promoter (6.8%), her tumor cells actively repair the DNA damage caused by standard temozolomide chemotherapy, severely limiting its effectiveness. The IO-VAC® protocol takes Grace’s own dendritic cells, exposes them to tumor neoantigens and Newcastle Disease Virus (NDV) in a GMP cleanroom, and re-infuses them to teach her cytotoxic CD8+ T cells to actively track and destroy glioblastoma stem cells across the blood-brain barrier.
Donations are deposited into a dedicated medical escrow account governed by the HopeRise UK Giving Guarantee. Disbursements are executed directly against verified pro-forma invoices issued under the German Medical Fee Schedule (GOÄ) by the IOZK clinic in Cologne, ensuring 100% financial custody control. Funds are never transferred into personal bank accounts.
Yes. Over 45% of all contributions are £5, £10, or £15 from students, university coursemates, and well-wishers nationwide. Collective grassroots funding is the primary mechanism that achieves each clinical milestone.
Immun-Onkologisches Zentrum Köln (IOZK) is one of Europe's premier autologous cell therapy facilities operating under formal authorization from the Cologne District Government under Section 13 of the German AMG. Furthermore, peer-reviewed clinical data published by Van Gool et al. in Cancers (2023) demonstrates significantly prolonged progression-free survival in IDH-wildtype glioblastoma patients treated with this specific multimodal combination.
Grace and her family publish verified clinical progress reports on this page every 2–3 weeks. These updates detail each travel stage, apheresis blood counts, post-vaccine immune monitoring panels, and official follow-up 3.0T cranial MRI findings reviewed by Salford Royal neurologists.
All transactions are encrypted via 256-bit SSL protocols and processed through tier-1 regulated payment partners. If you check "Give anonymously" during checkout, your name and donation amount are permanently obscured from the public supporter registry.
Yes. University student societies, NHS staff collectives, and organizational match-funders can arrange direct wire transfers into Grace’s segregated clinical escrow account. Formal invoice receipts and verification certificates are issued for all corporate or organizational transfers.
£35,090 raised of £90,000